DPP-4 inhibitor
Vildagliptin
VILDAGLIPTIN
Molecule level node. Arms of different doses of this comparator within a trial are combined into one arm.
Related
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.23 (0.00 to 13.54) | 0.57 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.24 (0.00 to 12.24) | 0.52 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.51 (0.01 to 33.34) | 0.66 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.48 (0.01 to 34.67) | 0.70 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.63 (0.01 to 45.64) | 0.55 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.49 (0.01 to 34.41) | 0.61 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.67 (0.01 to 56.02) | 0.61 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 1.66 (0.31 to 7.64) | 0.62 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 2.08 (0.39 to 9.85) | 0.44 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 1.03 (0.07 to 9.15) | 0.69 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 1.18 (0.09 to 10.96) | 0.60 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.18 (0.24 to 23.25) | 0.41 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.71 (0.29 to 28.84) | 0.31 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 3.43 (0.50 to 29.66) | 0.28 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 3.52 (0.54 to 30.14) | 0.23 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.74 (0.04 to 12.00) | 0.51 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.66 (0.04 to 11.04) | 0.45 |